Loading…

Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist

To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure. Two groups of rats ( n=6) w...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 2004-12, Vol.177 (1-2), p.35-45
Main Authors: JÄRBE, Torbjörn U. C, HARRIS, Michele Y, CHEN LI, QIAN LIU, MAKRIYANNIS, Alexandros
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63
cites cdi_FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63
container_end_page 45
container_issue 1-2
container_start_page 35
container_title Psychopharmacologia
container_volume 177
creator JÄRBE, Torbjörn U. C
HARRIS, Michele Y
CHEN LI
QIAN LIU
MAKRIYANNIS, Alexandros
description To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure. Two groups of rats ( n=6) were trained to discriminate between these drugs and vehicle in DTA ( t'=20 min). The 30-min drinking bout of tap water following drug (SR or THC) treatment was followed by an injection of lithium chloride (LiCl, 120 mg/kg) in the experimental animals. When offered water after vehicle pretreatment, experimental animals subsequently were given IP saline (NaCl, 10 ml/kg). Post-drinking treatment for controls ( n=6) was NaCl, irrespective of the pretreatment condition (SR, THC or vehicle). Additional water was provided during the afternoon (30 min) with no other manipulations. Food was available ad lib at all times. When the discriminations were established other doses and drugs were examined ( t'=20 min). In testing there were no post-drinking treatments. The SR-related analog AM-251 (dose range: 1-5.6 mg/kg) substituted for SR, whereas other drugs such as the cannabinoid CB(2) receptor antagonist SR-144528 (3 and 10 mg/kg), THC (1-10 mg/kg), flumazenil (1-10 mg/kg), naloxone (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not. There was a dose-related attenuation of SR-induced suppression of drinking when THC (1.8-10 mg/kg) was given together with SR (5.6 mg/kg). In the THC trained rats, SR (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not substitute for THC. SR (1 mg/kg) attenuated the THC (1.8 mg/kg) induced suppression of drinking. Together with 3 mg/kg SR and 1.8 mg/kg THC, drinking was roughly equally suppressed in both the experimental group and the controls. SR-141716 induces a discriminative stimulus complex in DTA that shows potential for further examination of cannabinoid receptor antagonism.
doi_str_mv 10.1007/s00213-004-1916-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67151325</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>754591731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63</originalsourceid><addsrcrecordid>eNpdkVuLFDEQhYMo7rj6A3yRICgKtqY690cdr7AgeHkONelEs_Qks0m34L83wwwsWC9FwVeHOnUIeQzsNTCm3zTGRuADY2IAC2qQd8gGBB-HkenxLtkwxvnAQZoL8qC1a9ZLGHGfXIAEpa2BDfn9PjVf0z5lXNKfQNuS9uu8NhpiDH5pNGVasfcS6fdvAwjQoOiLvlEy7jAvL19RpB5zn1IuaaLbd0Br8OGwlEo7gL9KTm15SO5FnFt4dO6X5OfHDz-2n4err5--bN9eDZ5LtQzTpA1HLtEYlGAmQBBMRg_W6h2XRuI4Ma68NVYhaqtFDDuho1ZWmBEVvyTPT7qHWm7W0Ba37w7DPGMOZW1O6W6ej7KDT_8Dr8tac7_NjWCs7L-CDsEJ8rW0VkN0h24d618HzB0zcKcMXKfdMQN3FH5yFl53-zDdbpyf3oFnZwCbxzlWzD61W04JrpUc-T8OiIwp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218950041</pqid></control><display><type>article</type><title>Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist</title><source>Springer Nature</source><source>SPORTDiscus with Full Text (EBSCO)</source><creator>JÄRBE, Torbjörn U. C ; HARRIS, Michele Y ; CHEN LI ; QIAN LIU ; MAKRIYANNIS, Alexandros</creator><creatorcontrib>JÄRBE, Torbjörn U. C ; HARRIS, Michele Y ; CHEN LI ; QIAN LIU ; MAKRIYANNIS, Alexandros</creatorcontrib><description>To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure. Two groups of rats ( n=6) were trained to discriminate between these drugs and vehicle in DTA ( t'=20 min). The 30-min drinking bout of tap water following drug (SR or THC) treatment was followed by an injection of lithium chloride (LiCl, 120 mg/kg) in the experimental animals. When offered water after vehicle pretreatment, experimental animals subsequently were given IP saline (NaCl, 10 ml/kg). Post-drinking treatment for controls ( n=6) was NaCl, irrespective of the pretreatment condition (SR, THC or vehicle). Additional water was provided during the afternoon (30 min) with no other manipulations. Food was available ad lib at all times. When the discriminations were established other doses and drugs were examined ( t'=20 min). In testing there were no post-drinking treatments. The SR-related analog AM-251 (dose range: 1-5.6 mg/kg) substituted for SR, whereas other drugs such as the cannabinoid CB(2) receptor antagonist SR-144528 (3 and 10 mg/kg), THC (1-10 mg/kg), flumazenil (1-10 mg/kg), naloxone (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not. There was a dose-related attenuation of SR-induced suppression of drinking when THC (1.8-10 mg/kg) was given together with SR (5.6 mg/kg). In the THC trained rats, SR (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not substitute for THC. SR (1 mg/kg) attenuated the THC (1.8 mg/kg) induced suppression of drinking. Together with 3 mg/kg SR and 1.8 mg/kg THC, drinking was roughly equally suppressed in both the experimental group and the controls. SR-141716 induces a discriminative stimulus complex in DTA that shows potential for further examination of cannabinoid receptor antagonism.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-004-1916-5</identifier><identifier>PMID: 15167981</identifier><identifier>CODEN: PSYPAG</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Biological and medical sciences ; Discrimination Learning - drug effects ; Discrimination Learning - physiology ; Dose-Response Relationship, Drug ; Drinking - drug effects ; Drinking - physiology ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Piperidines - pharmacology ; Pyrazoles - pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptor, Cannabinoid, CB1 - antagonists &amp; inhibitors ; Receptor, Cannabinoid, CB1 - physiology</subject><ispartof>Psychopharmacologia, 2004-12, Vol.177 (1-2), p.35-45</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Springer-Verlag 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63</citedby><cites>FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16437652$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15167981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JÄRBE, Torbjörn U. C</creatorcontrib><creatorcontrib>HARRIS, Michele Y</creatorcontrib><creatorcontrib>CHEN LI</creatorcontrib><creatorcontrib>QIAN LIU</creatorcontrib><creatorcontrib>MAKRIYANNIS, Alexandros</creatorcontrib><title>Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist</title><title>Psychopharmacologia</title><addtitle>Psychopharmacology (Berl)</addtitle><description>To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure. Two groups of rats ( n=6) were trained to discriminate between these drugs and vehicle in DTA ( t'=20 min). The 30-min drinking bout of tap water following drug (SR or THC) treatment was followed by an injection of lithium chloride (LiCl, 120 mg/kg) in the experimental animals. When offered water after vehicle pretreatment, experimental animals subsequently were given IP saline (NaCl, 10 ml/kg). Post-drinking treatment for controls ( n=6) was NaCl, irrespective of the pretreatment condition (SR, THC or vehicle). Additional water was provided during the afternoon (30 min) with no other manipulations. Food was available ad lib at all times. When the discriminations were established other doses and drugs were examined ( t'=20 min). In testing there were no post-drinking treatments. The SR-related analog AM-251 (dose range: 1-5.6 mg/kg) substituted for SR, whereas other drugs such as the cannabinoid CB(2) receptor antagonist SR-144528 (3 and 10 mg/kg), THC (1-10 mg/kg), flumazenil (1-10 mg/kg), naloxone (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not. There was a dose-related attenuation of SR-induced suppression of drinking when THC (1.8-10 mg/kg) was given together with SR (5.6 mg/kg). In the THC trained rats, SR (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not substitute for THC. SR (1 mg/kg) attenuated the THC (1.8 mg/kg) induced suppression of drinking. Together with 3 mg/kg SR and 1.8 mg/kg THC, drinking was roughly equally suppressed in both the experimental group and the controls. SR-141716 induces a discriminative stimulus complex in DTA that shows potential for further examination of cannabinoid receptor antagonism.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Discrimination Learning - drug effects</subject><subject>Discrimination Learning - physiology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drinking - drug effects</subject><subject>Drinking - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - pharmacology</subject><subject>Pyrazoles - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptor, Cannabinoid, CB1 - antagonists &amp; inhibitors</subject><subject>Receptor, Cannabinoid, CB1 - physiology</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkVuLFDEQhYMo7rj6A3yRICgKtqY690cdr7AgeHkONelEs_Qks0m34L83wwwsWC9FwVeHOnUIeQzsNTCm3zTGRuADY2IAC2qQd8gGBB-HkenxLtkwxvnAQZoL8qC1a9ZLGHGfXIAEpa2BDfn9PjVf0z5lXNKfQNuS9uu8NhpiDH5pNGVasfcS6fdvAwjQoOiLvlEy7jAvL19RpB5zn1IuaaLbd0Br8OGwlEo7gL9KTm15SO5FnFt4dO6X5OfHDz-2n4err5--bN9eDZ5LtQzTpA1HLtEYlGAmQBBMRg_W6h2XRuI4Ma68NVYhaqtFDDuho1ZWmBEVvyTPT7qHWm7W0Ba37w7DPGMOZW1O6W6ej7KDT_8Dr8tac7_NjWCs7L-CDsEJ8rW0VkN0h24d618HzB0zcKcMXKfdMQN3FH5yFl53-zDdbpyf3oFnZwCbxzlWzD61W04JrpUc-T8OiIwp</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>JÄRBE, Torbjörn U. C</creator><creator>HARRIS, Michele Y</creator><creator>CHEN LI</creator><creator>QIAN LIU</creator><creator>MAKRIYANNIS, Alexandros</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist</title><author>JÄRBE, Torbjörn U. C ; HARRIS, Michele Y ; CHEN LI ; QIAN LIU ; MAKRIYANNIS, Alexandros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Discrimination Learning - drug effects</topic><topic>Discrimination Learning - physiology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drinking - drug effects</topic><topic>Drinking - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - pharmacology</topic><topic>Pyrazoles - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptor, Cannabinoid, CB1 - antagonists &amp; inhibitors</topic><topic>Receptor, Cannabinoid, CB1 - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JÄRBE, Torbjörn U. C</creatorcontrib><creatorcontrib>HARRIS, Michele Y</creatorcontrib><creatorcontrib>CHEN LI</creatorcontrib><creatorcontrib>QIAN LIU</creatorcontrib><creatorcontrib>MAKRIYANNIS, Alexandros</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JÄRBE, Torbjörn U. C</au><au>HARRIS, Michele Y</au><au>CHEN LI</au><au>QIAN LIU</au><au>MAKRIYANNIS, Alexandros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist</atitle><jtitle>Psychopharmacologia</jtitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>177</volume><issue>1-2</issue><spage>35</spage><epage>45</epage><pages>35-45</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><coden>PSYPAG</coden><abstract>To examine the discriminative stimulus effects of (i) the cannabinoid CB(1) receptor antagonist SR-141716 (SR, 5.6 mg/kg) and vehicle, and (ii) the cannabinoid receptor agonist Delta(9)-THC (THC, 1.8 mg/kg) and vehicle using a discriminated taste aversion (DTA) procedure. Two groups of rats ( n=6) were trained to discriminate between these drugs and vehicle in DTA ( t'=20 min). The 30-min drinking bout of tap water following drug (SR or THC) treatment was followed by an injection of lithium chloride (LiCl, 120 mg/kg) in the experimental animals. When offered water after vehicle pretreatment, experimental animals subsequently were given IP saline (NaCl, 10 ml/kg). Post-drinking treatment for controls ( n=6) was NaCl, irrespective of the pretreatment condition (SR, THC or vehicle). Additional water was provided during the afternoon (30 min) with no other manipulations. Food was available ad lib at all times. When the discriminations were established other doses and drugs were examined ( t'=20 min). In testing there were no post-drinking treatments. The SR-related analog AM-251 (dose range: 1-5.6 mg/kg) substituted for SR, whereas other drugs such as the cannabinoid CB(2) receptor antagonist SR-144528 (3 and 10 mg/kg), THC (1-10 mg/kg), flumazenil (1-10 mg/kg), naloxone (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not. There was a dose-related attenuation of SR-induced suppression of drinking when THC (1.8-10 mg/kg) was given together with SR (5.6 mg/kg). In the THC trained rats, SR (1-10 mg/kg), morphine (10 and 18 mg/kg) and d-amphetamine (1 and 3 mg/kg) did not substitute for THC. SR (1 mg/kg) attenuated the THC (1.8 mg/kg) induced suppression of drinking. Together with 3 mg/kg SR and 1.8 mg/kg THC, drinking was roughly equally suppressed in both the experimental group and the controls. SR-141716 induces a discriminative stimulus complex in DTA that shows potential for further examination of cannabinoid receptor antagonism.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>15167981</pmid><doi>10.1007/s00213-004-1916-5</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacologia, 2004-12, Vol.177 (1-2), p.35-45
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_miscellaneous_67151325
source Springer Nature; SPORTDiscus with Full Text (EBSCO)
subjects Animals
Biological and medical sciences
Discrimination Learning - drug effects
Discrimination Learning - physiology
Dose-Response Relationship, Drug
Drinking - drug effects
Drinking - physiology
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Piperidines - pharmacology
Pyrazoles - pharmacology
Rats
Rats, Sprague-Dawley
Receptor, Cannabinoid, CB1 - antagonists & inhibitors
Receptor, Cannabinoid, CB1 - physiology
title Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T22%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discriminative%20stimulus%20effects%20in%20rats%20of%20SR-141716%20(rimonabant),%20a%20cannabinoid%20CB1%20receptor%20antagonist&rft.jtitle=Psychopharmacologia&rft.au=J%C3%84RBE,%20Torbj%C3%B6rn%20U.%20C&rft.date=2004-12-01&rft.volume=177&rft.issue=1-2&rft.spage=35&rft.epage=45&rft.pages=35-45&rft.issn=0033-3158&rft.eissn=1432-2072&rft.coden=PSYPAG&rft_id=info:doi/10.1007/s00213-004-1916-5&rft_dat=%3Cproquest_cross%3E754591731%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-dd783a35a88a518d1a1405fc1997b3585a2d036c9896aa7974feb47f769482a63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218950041&rft_id=info:pmid/15167981&rfr_iscdi=true